Factor | Quintana.Hayashi_2012_AppandEnvMic (10322)

10.1128/AEM.07723-11

Enrofloxacin use

Swine | Sows

2

Description

50 mg, injected. Predominantly C. coli (98.3%).

Resistance Outcomes

Resistance Microbe Outcome
Nalidixic Acid
/
Campylobacter coli
See: Table 4 AMR+ (n) AMR- (n) Total (n)
Enrofloxacin use 5 60
No use 0 142
Ciprofloxacin
/
Campylobacter coli
See: Table 4 AMR+ (n) AMR- (n) Total (n)
Enrofloxacin use 5 60
No use 0 142